Special Series| AI Reckoning Ep 2: From Molecule to Market — 173 AI Drugs in Trials, But Phase 2 Data Tells a Different Story

173 AI-discovered drugs in clinical development. Phase 1 success rates of 80-90% vs 52% traditional. But at Phase 2, the AI advantage disappears — and nobody's talking about it. We unpack rentosertib's Nature Medicine data, zasocitinib's Phase 3 win, the Recursion pipeline reality, synthetic control arms cutting trial timelines by18 months, the FDA's 7-step AI credibility framework, and what this means for R&D careers. Episode 2 of "The AI Reckoning: Pharma's Make-or-Break Moment."